Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 [Yahoo! Finance]
Minerva Neurosciences, Inc (NERV)
Last minerva neurosciences, inc earnings: 3/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.minervaneurosciences.com/investor-relations
Company Research
Source: Yahoo! Finance
The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open-label safety trial evaluating roluperidone co-administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy. The presentation titled “A Study of Roluperidone Coadministered with Olanzapine in Patients with Negative Symptoms of Schizophrenia” is being delivered by Michael Davidson, MD, Chief Medical Officer of Minerva Neurosciences and highlights safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings from the trial. The trial was desi
Show less
Read more
Impact Snapshot
Event Time:
NERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NERV alerts
High impacting Minerva Neurosciences, Inc news events
Weekly update
A roundup of the hottest topics
NERV
News
- Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026GlobeNewswire
- Minerva Neurosciences (NERV) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock, up from $4.00.MarketBeat
- Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumGlobeNewswire
- Minerva Neurosciences files $200M mixed shelf registration [Seeking Alpha]Seeking Alpha
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
NERV
Earnings
- 5/13/25 - Beat
NERV
Analyst Actions
- 3/12/26 - HC Wainwright
NERV
Sec Filings
- 3/20/26 - Form EFFECT
- 3/11/26 - Form S-3
- 3/11/26 - Form 10-K
- NERV's page on the SEC website